TKT and glioblastoma: The anti-glioblastoma effects of Si306 and pro-Si306 demonstrated in this study, as well as previously obtained results in vitro and in vivo, particularly the ability of these TK inhibitors to cross the blood–brain barrier, give prospects for clinical trials of these compounds as potential candidates for glioblastoma therapy.